Brookline Capital Management Forecasts C4 Therapeutics FY2029 Earnings

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Analysts at Brookline Capital Management issued their FY2029 earnings per share estimates for C4 Therapeutics in a research report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann expects that the company will earn $28.08 per share for the year. The consensus estimate for C4 Therapeutics’ current full-year earnings is ($1.52) per share.

A number of other research analysts also recently issued reports on CCCC. Stephens initiated coverage on shares of C4 Therapeutics in a research note on Monday, November 18th. They issued an “equal weight” rating and a $4.00 price target for the company. Wells Fargo & Company raised shares of C4 Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $8.00 to $12.00 in a research report on Thursday, December 19th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.67.

C4 Therapeutics Stock Performance

Shares of CCCC opened at $3.84 on Wednesday. The company’s 50-day simple moving average is $4.44 and its 200-day simple moving average is $5.38. C4 Therapeutics has a 1 year low of $3.43 and a 1 year high of $11.88. The stock has a market capitalization of $271.06 million, a PE ratio of -2.26 and a beta of 2.96.

C4 Therapeutics (NASDAQ:CCCC) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.05. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. The firm had revenue of $15.36 million for the quarter, compared to the consensus estimate of $5.95 million.

Institutional Trading of C4 Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CCCC. Point72 Asset Management L.P. boosted its stake in C4 Therapeutics by 331.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,201,848 shares of the company’s stock worth $6,851,000 after purchasing an additional 923,268 shares during the period. Acadian Asset Management LLC increased its holdings in shares of C4 Therapeutics by 415.8% in the second quarter. Acadian Asset Management LLC now owns 113,436 shares of the company’s stock valued at $524,000 after purchasing an additional 91,443 shares during the period. Wasatch Advisors LP raised its stake in shares of C4 Therapeutics by 17.1% during the third quarter. Wasatch Advisors LP now owns 5,677,368 shares of the company’s stock worth $32,361,000 after purchasing an additional 830,218 shares during the last quarter. FMR LLC raised its stake in shares of C4 Therapeutics by 687.0% during the third quarter. FMR LLC now owns 185,941 shares of the company’s stock worth $1,060,000 after purchasing an additional 162,314 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of C4 Therapeutics during the second quarter worth $881,000. 78.81% of the stock is owned by hedge funds and other institutional investors.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.